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100,000-member health care plan. METHODS: Patient characteristics and AED ef-
ficacy (decrease from baseline in frequency of drop seizures) were modeled with
clinical trial data. Medical costswere derived fromadministrative claims data from
a large US managed health care plan affiliated with OptumInsight, with the as-
sumption that 2.3% of drop seizures required medical care. Budget impact was
measured over 2 years. Results were expressed as overall difference in costs (sei-
zure and pharmacy) to a health plan, and cost permember permonth (PMPM) after
the addition of clobazam. Alternative scenario analyseswere performed.RESULTS:
With the assumption that 0.04 % of the plan population had LGS, addition of clo-
bazam to the formulary resulted in cost savings of $78,600 in Year 1 and $104,000 in
Year 2, corresponding to savings of $0.07 and $0.09 PMPM, respectively. Alternative
analyses with lower seizure rates upon discontinuation or greater long-term effi-
cacy for lamotrigine and topiramate did not substantially alter the conclusion.
Assumption that fewer drop seizures require medical care resulted in a modest
cost increase with clobazam, suggesting that medically attended drop seizures are
a primary driver of costs for LGS patients. CONCLUSIONS:Medically attended drop
seizures are a major cost driver for LGS patients. Our results demonstrate that
adding clobazam to a health care plan formulary can have a positive overall budget
impact through a decrease in medical costs associated with drop seizures.
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OBJECTIVES: To develop a budget impact (BI) and cost-effectiveness (CE) model to
determine the effect of introducing the recently approved once-daily gabapentin
(Gralise™; G-QD) into the existing market of postherpetic neuralgia (PHN)
treatments.METHODS: The BImodel is based on estimated US. PHN incidence and
captures treatment costs from initiation of PHN therapy through sixmonths. Initial
treatments included G-QD, gabapentin TID, and pregabalin. After assessment at 10
weeks, patients could remain on initial monotherapy, or add, switch, or discon-
tinue PHN treatments. Post-assessment therapies also included lidocaine patch
and opioids. Clinical and epidemiological data sources consisted of clinical trial
data, US census data, and published literature. The US payer perspective model
includes direct medical costs (in 2010 US dollars) including pharmacy, physician
visits, and treatment of adverse events. Discounting was excluded due to the short
timeframe. Drugs were priced at wholesale average cost (WAC). Other pricing fac-
tors were co-pays and rebates. Cost sources included proprietary standardized
databases, Medicare fee schedules, and published literature. The CE analysis was
based on a hypothetical 1000-patient cohort. Patientswith andwithout pain reduc-
tion were determined from clinical trial data; outcomes were quality adjusted
based on published PHN utility data for pain and adverse events. Costs were taken
from the BI analysis. RESULTS: For 34,183 PHN patients, the addition of G-QD
decreased the total cost budget by $12,230 (-0.04%). While the pharmacy budget
increased by $299,547 (1.34%), the non-pharmacy budget decreased by $311,777
(-3.06%). In the CE analysis, the incremental cost per quality-adjusted life year was
$31,257 for G-QD versus gabapentin TID, and G-QD dominated pregabalin. Sensi-
tivity analysis demonstrated stable results. CONCLUSIONS: The budget impact of
introducing G-QD to the market is small when considering only pharmacy costs,
but may be cost saving when non-pharmacy costs are included. G-QD is cost-
effective versus other initial PHN treatments.
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OBJECTIVES: Polyethylene glycol-conjugated (PEGylated) therapies are commonly
used to treat patients with anemia, neutropenia, and viral hepatitis. While no
PEGylated drugs are currently approved for the treatment of multiple sclerosis
(MS), a PEGylated formulation of interferon beta-1a is being developed for relaps-
ing-remitting MS treatment. The goal of this study was to identify the economic
benefits of PEGylated drugs currently available in other disease areas.METHODS:A
comprehensive search of the medical literature was conducted using PubMed/
MEDLINE, article links, and supplemental searches. Inclusion criteria included Eng-
lish language, publication date between 1985 and 2010, prospective or retrospective
study design, and cost or cost-effectiveness studies comparing PEGylated drugs
with their non-PEGylated counterparts in the same therapeutic area. All costs were
adjusted to 2010 US dollars for reporting. RESULTS: Thirty-seven published articles
reporting data from 11 countries in 12 therapeutic areas were reviewed, including
studies on pegfilgrastim, liposomal PEGylated doxyrubicin, peginterferon alfa 2a
and 2b, pegaspargase, and PEGylated epoetin. Twelve studies showed some cost
offsets for 6 PEGylated drugs, with 4 of the drugs reducing administration costs.
Other offset costs included those for adverse event treatment, disease complica-
tions, and inpatient/outpatient treatment. Nineteen of the 35 studies considering
total treatment costs showed total cost savingswith 3 of 5 PEGylated drugs, ranging
up to $7743 per patients annually.With 4 PEGylated drugs, 17 of 18 studies reported
incremental cost-effectiveness ratios below $50,000 per quality-adjusted life-year.
CONCLUSIONS: PEGylated drugs are reported to reduce patient health resource use
and costs, including costs associatedwith drug administration and adverse events.
Since multiple studies have demonstrated that PEGylated drugs are more cost-
effective than their non-PEGylated counterparts, PEGylated interferon beta-1amay
offer similar economic benefits to payers and health care systems.
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OBJECTIVES: Little US data are available on the costs of HD, a debilitating disease
marked by motor/cognitive/psychiatric impairment worsening through distinct
disease stages. Our study aimed to quantify the direct health care costs (andmajor
cost drivers) among HD patients by disease stage in commercial (C) versus Medic-
aid (M) databases.METHODS: Health care utilization/cost data (pharmacy, outpa-
tient, inpatient) were obtained for HD patients (ICD-9-CM 333.4) from Thomson
Reuters’ MarketScan M/C 2002-2009 databases. Patients were classified by disease
stage (early/middle/late) via a hierarchical assessment ofmarkers of disease sever-
ity, whichwas confirmed by literature review/key opinion leader input. Health care
utilization/costs were measured over the follow-up time of each patient with total
costs/patient/stage annualized using a patient-year cost approach. RESULTS: A
total of 1272 HD patients (752/520 C/M) were included for this study. The mean age
was similar between the two populations (C: 48.5 years (SD 13.3); M: 49.3 years (SD
17.2)) with slightly higher female representation in the M population (60.8% vs.
54.1%). A fairly even C patient distribution by stage was noted (30.5%/35.5%/34.0%;
early/middle/late). However, most (74.0%) M HD patients were classified as late
stage. Themean total annualized cost per patient varied in both populations (early:
C - $4,947 (SD $6,040), M - $3,257 (SD, $5,670); middle: C - $15,066 (SD $21,722), M -
$12,330 (SD $16,986); late: C - $22,582 (SD $39,028), M - $37,495 (SD $27,111)). Outpa-
tient costs were the primary health care cost component, except for M early stage
(outpatient: early: C – 45.8%; middle: C – 48.2%, M – 66.4%; late: C – 41.5%, M – 78.9%;
inpatient: early: M - 37.7%). Nursing home costs contributed to 54.6% of M but only
4.6% of C total late stage costs. CONCLUSIONS: HD direct health care costs in-
creasedwith disease progression. Late stageM patients had higher costs than their
C counterparts, due to nursing home costs.
PND10
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OBJECTIVES: To describe diagnosis codes, frequency and cost of multiple sclerosis
(MS)-related hospital and emergency room (ER) utilization.METHODS:Two cohorts
of MS-diagnosed patients aged 18-64 years were selected from a national managed
care database: 1) longitudinal cohort: patients with 12 months pre/post eligibility
around first MS diagnosis occurring January 1, 2002 to July 30, 2010, and 2) cross-
sectional cohort: patients with an MS diagnosis in 2010. MS-related [multiple scle-
rosis (ICD-9-CM340.XX), other demyelinating CNS disease (ICD-9-CM341.XX),
and a group of symptom-related codes] hospitalizations and ER visits were evalu-
ated. Rehabilitation (ICD-9-CMV57.89) was included based on qualitative review
of codes. Mean number and cost per patient, adjusted to $US 2010, were described.
RESULTS:Therewere 31,905 patients in the longitudinal cohort and 32,845 patients
in the cross-sectional cohort. In the longitudinal cohort, 18.5% had a post-index
hospitalization (any cause) with 5.2% being MS-related (340.XX: 3.2%; 341.XX: 0.4%;
rehabilitation: 0.8%; and symptom-related: 1.1%). Mean number and cost (SD) of an
MS-related hospitalization were 1.19 (0.55) and $14,358 ($32,356), respectively. In
addition, 31.4% of patients experienced a post-index ER visit with 6.9% being MS-
related (340.XX: 2.9%; 341.XX: 0.2%; symptom-related: 4.7%).Meannumber and cost
(SD) of an MS-related ER visit were 1.23 (0.78) and $573 ($816), respectively. In the
cross-sectional cohort, 12.5% had a hospitalization (any cause) with 3.7% being
MS-related (340.XX: 2.1%; 341.XX: 0.2%; rehabilitation: 1.1%; and symptom-related:
0.7%). Mean number and cost (SD) of an MS-related hospitalization were 1.32 (0.78)
and $16,213 ($25,394), respectively. In addition, 27.3% of patients experienced an ER
visit with 6.4% beingMS-related (340.XX: 2.6%; 341.XX: 0.1%; and symptom-related:
4.5%).Meannumber and cost (SD) of anMS-related ER visitwere 1.37 (0.89) and $682
($825), respectively. CONCLUSIONS: Costs for hospitalization and ER visits among
MS patients were substantial. Inclusion of rehabilitation and symptom-related
codes can account for an under-recognized proportion of expenditures.
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OBJECTIVES: Cervical dystonia (CD), or spasmodic torticollis (333.83), is the most
common adult-onset focal dystonia and is associated with significant pain and
disability. The quality of life burden of CD has been well documented; however,
very limited information exists regarding the economic burden of CD. This study
aims to quantify the average per-patient cost of CD health care resource use using
baseline data from the CD Patient Registry for the Observation of Onabotulinum-
toxinA Efficacy (CD PROBE), a large ongoing registry. METHODS: At baseline, par-
ticipants reported use of specific health care resources over the preceding 6
months, including visits to a primary care provider, neurologist, physiatrist, phys-
ical or occupational therapist, neurosurgeon, alternative care provider, chiroprac-
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tor, emergency department (ED), or “other,” as well as the number of CD-related
hospital admission days. Unit costs were assigned to each type of health care
resource using national non-Medicare 2011 reimbursement rates. Hospitalization
cost was estimated using the HCUP.net mean daily cost of inpatient stay (principal
diagnosis 333.83). Cost of an ED visit was estimated by the mean paid amount for
ED visit (principal diagnosis 333.83) using commercial claims data. RESULTS: Base-
line data were available for 786 participants at time of analysis. The mean age was
57.7 years, and the majority (76%) were female. The mean (SD) number of visits to
a primary care providerwas 1.4 (2.1), 1.9 (1.9) for neurologist, 0.7 (1.8) for physiatrist,
1.8 (3.8) for physical/occupational therapy, 0.2 (0.9) for neurosurgeon, 1.3 (3.1) for
alternative care provider, 1.1 (3) for chiropractor, and 3.2 (2.7) for “other.” Partici-
pants reported amean(SD) of 0.2(0.9) visits to the ED and 0.1(0.6) hospital admission
days. The mean total cost of CD over 6 months was $1,255.80 (range $0-$63,320.20;
median $639.80). The largest single cost driver was the number of hospital admis-
sion days. CONCLUSIONS: The economic impact of CD-related health care re-
source use should not be overlooked when assessing disease burden.
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OBJECTIVES: The economic burden of Multiple Sclerosis (MS) on society and the
individuals concerned is not known. Documenting such costs is essential for sev-
eral reasons: costs of illness is a key factor of optimal diseasemanagement policies,
knowledge of cost is useful for allocating research anddevelopment. The aimof our
study as the first pharmacoeconomic investigation in Iran was to estimate the
costs of multiple sclerosis according to severity of disease.METHODS: Total, direct
and indirect costs were compared in 160 patients divided into three groups cate-
gorized by disease severity: stage I Expanded Disability Status Scale (EDSS 2.5),
stage II (EDSS 3- 4.5) and stage III (EDSS 5).The majority of these patients (94%)
developed relapsing- remitting MS.A minority of the patients (0.2-4 %) developed
secondary progressive and primary progressive MS. Cost evaluation was per-
formed from the societal perspective and covered the one-year period. The study
was carried out at the Division of Neurology at GhaemHospital andMS association
in Mashhad in northeast of Iran and was approved by the local ethics committee.
RESULTS: The mean total cost/patient for one year was estimated at $27,095,
$27,997and $31,662 for stage I, II and III, respectively. Both direct and indirect costs
increased with MS progression. For indirect cost the main item was productivity
loss. Themean extramedicine (treatments forMS symptoms and adverse effects of
medications) cost/patient for one year was calculated at $19,036. CONCLUSIONS:
This study confirms that MS represents a high economic burden to patients and
society, with direct costs greatly exceeding indirect costs. As costs increase with
disease progression, treatment efforts should focus on patients in the early stages
of MS. Disease support system that monitors a variety of common progressive
signs for the MS individuals is a key element of a management program as well.
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OBJECTIVES: Seizure control through antiepileptic drugs (AEDs) is integral to treat-
ment of Lennox-Gastaut syndrome (LGS). Although six AEDs are approved for LGS
(clobazammost recently, October 2011), no standard treatment paradigm has been
established. Understanding the economic burden associated with LGS is critical to
developing such guidance. The objective of this study was to examine health care
resource utilization and costs for patients with LGS.METHODS:Medical and phar-
macy claims data (1/1/2007–9/30/2010) from a large US managed health care plan
affiliated with OptumInsight were analyzed. Study patients were those with evi-
dence of LGS based on 2medical claims (30 days apart) with diagnosis (ICD-9-CM)
of generalized, nonconvulsive (or convulsive) epilepsy. Evidence of developmental
diagnoses and 12 months of continuous health plan enrollment following initial
epilepsy diagnosis were required. Health care resource utilization and costs were
examined during a 12-month follow-up period and computed separately as all-
cause, epilepsy-related (i.e., any epilepsy care), or related to seizure-attributable
events (e.g., lacerations, fractures). RESULTS: A total of 1,948 patients with evi-
dence of LGS were identified; demographics were consistent with published sur-
veys. Mean counts of epilepsy-related health care visits at 12 months were 10.73
(all-cause: 33.97) for ambulatory visits and 0.75 (all-cause: 0.86) for inpatient ad-
missions. Mean epilepsy-related health care cost was $29,911 (all-cause: $44,797),
of which the greatest components were inpatient costs (epilepsy-related: $18,119;
all-cause: $19,590) and ambulatory costs (epilepsy-related: $5,515; all-cause: $11,907).
Meanmedical cost related to seizure-attributable eventswas$13,038.CONCLUSIONS:
A high economic burden was observed in this LGS sample, with frequent health
care visits and high costs attributable to epilepsy care. Nearly one-third of total
medical costs were associated with seizure-attributable events, highlighting the
need for effective seizure control. These results will be useful for understanding
the budgetary impact and cost effectiveness of AED therapy in LGS treatment.
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OBJECTIVES: The majority of epileptic patients manage their condition with anti-
epileptic drugs (AEDs) to prevent seizures. Despite being adherent to AEDs, some
patients fail to have adequate seizure control; therefore, they have refractory epi-
lepsy. This study assessed the health care costs and resource utilization of epilepsy
patients with partial onset seizures (POS) who were refractory compared to non-
refractory patients.METHODS:Administrative claims from 2004-2008 in a US com-
mercially insured population were analyzed. Patients aged 18-64 years were se-
lected if they had medical claims with POS (ICD-9-CM codes: 345.4, 345.5). This
study used an operational definition of 3 different AED agents dispensed as refrac-
toriness. Patients were considered refractory from the year they received the third
AED and forward. Annual direct health care utilization and costs within each cal-
endar year among patients who were continuously enrolled were compared be-
tween refractory and non-refractory cohorts. RESULTS: The study identified 79,149
patients with POS (mean age 33 years; 54.8% female), and 8,714 (11%) patients
became refractory. In 2008, refractory patients were more likely to have a hospital
admission (27.2% vs. 16.9%; p0.001). Average annual health care costs for refrac-
tory patients were significantly higher than non-refractory patients ($33,613 vs.
$19,085; p0.001), as well as by settings for inpatient ($11,780 vs. $6,076; p0.001),
outpatient ($12,677 vs. $8,125; p0.001) and pharmacy costs ($5,280 vs. $2,256;
(p0.001). Close to half of total costs were attributable to POS-related services.
Similar trends were observed when assessing POS-related costs and utilization.
The differences were consistent across calendar years examined. CONCLUSIONS:
The findings from this study suggest refractoriness in epilepsy patients with POS is
associated with high economic burden from the health insurer’s perspective. Re-
fractory patients incurred 76%more healthcare costs than non-refractory patients.
Improving seizure control and reducing the economic burden of refractory epilepsy
remain important unmet medical needs in this population.
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OBJECTIVES: This study estimated health care resource utilization (HCRU) and
medical costs in both pediatric and adult Medicaid populations, comparing epilep-
sy-related costs with overall costs. METHODS: A retrospective analysis was con-
ducted using Thomson Reuters’ Medicaid claims data from 13 states (2005-2009).
Epilepsy patients were identified through ICD-9 code 345.xx and 780.39. Annual
HCRU and medical costs (in 2009 dollars) in adult (18 years) and pediatric pa-
tients (2-17 years) were estimated separately. HCRU was considered as epilepsy-
related if it was associated with ICD-9 code of 345.xx or 780.39, or was an anti-
epileptic drug. RESULTS: A total of 75,111 patients were identified with epilepsy,
with 31,484 pediatric (mean age 8.8 years) and 43,627 adult (mean age 40.4 years).
Annually, a pediatric patient with epilepsy incurred 0.23 hospital admissions (0.13
epilepsy-related), 1.31 ER visits (0.38 epilepsy-related), 6.12 physician office visits
(1.25 epilepsy-related), 3.25 outpatient hospital visits (0.91 epilepsy-related), 27.17
other outpatient visits (1.62 epilepsy-related), 22.3 prescriptions (3.96 epilepsy-re-
lated). Among adult patients, average HCRU was 0.90 hospital admissions (0.43
epilepsy-related), 3.52 ER visits (0.66 epilepsy-related), 10.26 physician office visits
(1.62 epilepsy-related), 7.44 outpatient hospital visits (1.07 epilepsy-related), 58.69
other outpatient visits (2.65 epilepsy-related), 71.43 prescriptions (10.1 epilepsy-
related). Direct medical costs per patient were $10,669 (18.4% epilepsy-related) for
a pediatric patient and $29,886 (17.7% epilepsy-related) for an adult patient. Overall
directmedical costs associated with active epilepsy in the identifiedMedicaid pop-
ulation were $293 million ($62 million for pediatric and $231 million for adult).
CONCLUSIONS: Non-epilepsy related HCRU and direct medical costs dominated
HCRU and direct medical costs in Medicaid patients with epilepsy, indicating that
substantial comorbidities are associated with epilepsy patients in the Medicaid
population. Adult patients had higher HCRU and direct medical costs compared to
pediatric patients, which may be related to likely differences in the types of epi-
lepsy experienced by children and adults.
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ECONOMIC EVALUATION OF PREGABALIN AND GABAPENTIN FOR
NEUROPATHIC PAIN FROM THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
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OBJECTIVES: Based on the work of Sicras-Mainar et al. 2011, evaluating real world
data on the resource consumption of patients treated with pregabalin and gabap-
entin for neuropatic pain, an adaptation to the Brazilian public health care system
was carried in order to compare both strategies. METHODS: A cost-minimization
study was designed considering the length of treatment, daily dose strengths dis-
tributions, hospitalization days, medical visits, physiotherapy sessions and other
concomitant medications used. Frequencies and resource use was obtained from
the aforementioned study, and prices were retrieved from national databases
(Banco de Preços em Saúde and SIGTAP - Sistema de Gerenciamento da Tabela de
Procedimentos, Medicamentos e OPM do SUS). To best represent the values for the
not-normal distribution of length of treatment frequencies reported in the study, a
Monte Carlo simulation using 10.000 iterationswas carried considering a triangular
distribution. The timehorizonwas defined as 1 year. Valueswere expressed in 2011
USD. RESULTS:The overall costs ofmedications compared in this study per patient
were 332.74 and 291.20 USD for pregabalin and gabapentin, respectively. Health
care utilization costs were 89.12 and 128.76 USD for pregabalin and gabapentin
treated patients respectively. Other concomitant medication costs were 56.29 and
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